Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1997-11-14
|
pubmed:abstractText |
The anti-allergic activity of betotastine besilate (betotastine), a new anti-allergic drug, was investigated in several allergy models of rats in comparison with other anti-allergic drugs.1) Orally administered betotastine (0.1-30 mg/kg) inhibited homologous passive cutaneous anaphylaxis (PCA) in rats in a dose-dependent manner (ID30-value: 0.38 mg/kg). The inhibitory activity of betotastine was significant at 1 mg/kg and was more potent than that of ketotifen, terfenadine, cetirizine and epinastine. The PCA-inhibitory activity of betotastine lasted more than 8 hr after administration, and the repeated administration of betotastine lasted more than not induce drug-tolerance. 2) Orally administered betotastine inhibited the histamine-induced skin reaction in rats in a dose-dependent manner (ID30:0.10 mg/kg), and the inhibitory activity lasted more than 4 hr after the administration. Its inhibitory activity was significant at 0.1 and 1 mg/kg and was more potent than those of ketotifen, terfenadine, cetirizine and epinastine. 3) Betotastine suppressed histamine release from rat peritoneal mast cells at a high concentration (10(3)(10(-3)M). These results suggest that betotastine has a potent and long acting anti-allergic activity, and these effects are mainly due to histamine antagonistic activity.
|
pubmed:language |
jpn
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Allergic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Arachidonic Acids,
http://linkedlifedata.com/resource/pubmed/chemical/Histamine Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Piperidines,
http://linkedlifedata.com/resource/pubmed/chemical/Pyridines
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0015-5691
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
110
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
19-29
|
pubmed:dateRevised |
2011-7-27
|
pubmed:meshHeading |
pubmed-meshheading:9285833-Administration, Oral,
pubmed-meshheading:9285833-Animals,
pubmed-meshheading:9285833-Anti-Allergic Agents,
pubmed-meshheading:9285833-Arachidonic Acids,
pubmed-meshheading:9285833-Capillary Permeability,
pubmed-meshheading:9285833-Cells, Cultured,
pubmed-meshheading:9285833-Depression, Chemical,
pubmed-meshheading:9285833-Dose-Response Relationship, Drug,
pubmed-meshheading:9285833-Histamine Antagonists,
pubmed-meshheading:9285833-Histamine Release,
pubmed-meshheading:9285833-Male,
pubmed-meshheading:9285833-Mast Cells,
pubmed-meshheading:9285833-Passive Cutaneous Anaphylaxis,
pubmed-meshheading:9285833-Piperidines,
pubmed-meshheading:9285833-Pyridines,
pubmed-meshheading:9285833-Rats,
pubmed-meshheading:9285833-Rats, Sprague-Dawley
|
pubmed:year |
1997
|
pubmed:articleTitle |
[Anti-allergic activity of betotastine besilate (TAU-284), a new anti-allergic drug].
|
pubmed:affiliation |
Pharmaceutical Development Research Laboratory, Tanabe Seiyaku Co. Ltd., Saitama, Japan.
|
pubmed:publicationType |
Journal Article,
English Abstract
|